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Voiding Dysfunction
The Different Reduction Rate of Prostate-Specific Antigen in 
Dutasteride and Finasteride
Yong Hyeuk Choi, Sung Yong Cho, In Rae Cho
Department of Urology, College of Medicine, Inje University, Goyang, Korea
Purpose: To compare and analyze the therapeutic effects and changes in the pros-
tate-specific antigen (PSA) level with treatment with finasteride or dutasteride for be-
nign prostatic hyperplasia (BPH) for 1 year.
Materials and Methods: We retrospectively investigated patients who suffered from 
BPH for 1 year between January 2005 and December 2008. For treatment groups, we 
divided the patients into two groups: one was treated with alfuzosin and finasteride 
and the other was treated with alfuzosin and dutasteride. At the beginning of treat-
ment, the patients underwent transrectal ultrasonography and measurement of urine 
flow rate, residual urine volume, PSA, and International Prostate Symptom Score 
(IPSS). Patients with diseases affecting urinary function were excluded. We not only 
analyzed the data at the time of initial treatment, but also after 1 year of treatment. 
A total of 219 patients were able to be evaluated for 1 year.
Results:  Both finasteride and dutasteride reduced PSA and prostate volume 
significantly. The comparison between groups showed a more significant reduction of 
PSA (p=0.020) and prostate volume (p=0.052) in the dutasteride group. Other parame-
ters did not differ significantly between the groups.
Conclusions: 5-α Reductase inhibitors for BPH treatment reduced PSA and prostate 
volume significantly when the patients were treated for 1 year. Administration of dutas-
teride is considered to be more effective in reducing PSA and prostate volume. 
Therefore, dutasteride should not be considered equivalent to finasteride in the reduc-
tion rate of PSA. The intensity of dutasteride must be reevaluated in comparison with 
finasteride.
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INTRODUCTION
Benign prostatic hyperplasia (BPH) is a disease in which 
lower urinary tract symptoms are concurrently present 
while the prostate is gradually enlarged. It has been re-
ported to occur in more than approximately 50% of males 
aged 60 years or older. Due to the increased mean life ex-
pectancy, the importance of BPH has increased [1]. Accor-
dingly, in recent years, drug therapy has been used as a 
mainstream modality in most patients [2]. α-blockers and 
5-α-reductase inhibitors (5ARIs) are representative of 
these treatment agents. In particular, useful treatment 
outcomes have been reported after long-term use of 5ARIs.
　5AR is classified into type I and type II. Both types are 
increasingly expressed in cases of BPH compared with nor-
mal tissue. However, in cases of primary prostate cancer, 
type I 5AR is increased. By contrast, type II 5AR is de-
creased or remains unchanged as compared with BPH [3]. 
In addition, type II is increased when local prostate carcino-
ma progresses to metastatic cancer. Both types I and II are 
increased in high-grade carcinoma compared with low- 
grade carcinoma [4]. 
　Of the 5ARIs that are currently used in Korea, finas-
teride selectively inhibits type II. By contrast, dutasteride Korean J Urol 2010;51:704-708
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TABLE 1. The comparison of medication effect parameters according to patient group 
Basement 1 year later
Differences between 
basement and 1 year later p-value
Group 1 Group 2 Group 1 Group 2 Group 1 Group 2
Prostate volume (g) 37.3±21.7 38.5±14.2 32.4±19.8 31.9±12.8 4.9±6.9 6.6±7.5 0.084
PSA (ng/ml) 2.32±2.93 2.27±2.15 1.48±1.60 1.47±1.79 0.80±2.30 0.80±1.10 0.886
Qmax (ml/s) 14.2±6.8 13.5±6.3 14.5±7.2 14.8±7.5 0.3±6.7 1.3±6.5 0.299
Voided volume (ml) 206.7±131.5 207.1±130.7 213.0±243.6 207.1±130.7 6.6±223.6 1.3±116.0 0.851
Residual urine volume (ml)  42.2±45.0 48.7±56.6 27.3±28.9 28.7±25.4 14.8±39.9 20.0±52.7 0.409
IPSS
  Total score 14.5±8.0 15.7±7.6 11.1±7.6 11.6±7.1 3.4±6.3 4.1±6.2 0.430
  Quality of life score 2.7±0.6 2.8±0.7 2.5±1.0 2.4±1.0 0.2±0.9 0.4±0.8 0.083
Group 1: alfuzosin＋finasteride group, Group 2: alfuzosin＋dutasteride group, PSA: prostate-specific antigen, Qmax: urine peak flow
rate, IPSS: International Prostate Symptom Score
TABLE 2. Comparison of parameter ratios according to patient 
group after 1 year of treatment 
Group 1 
(n=136)
Group 2 
(n=83)
p-value 
Prostate volume ratio 0.87±0.14 0.83±0.16 0.052
PSA ratio 0.85±0.62 0.67±0.39 0.019
a
Qmax ratio 1.14±0.57 1.41±2.07 0.163
Voided volume ratio 1.46±3.13 1.26±0.95 0.575
Residual urine volume ratio 1.05±1.08 1.00±0.89 0.724
IPSS
  Total score ratio 1.02±0.78 0.98±0.47 0.764
  Quality of life score ratio 0.97±0.35 0.91±0.32 0.247
Group 1: alfuzosin＋finasteride group, Group 2: alfuzosin＋du-
tasteride group, ratio: value of pre-medication/value of post-medi-
cation, PSA: prostate-specific antigen, Qmax: urine peak flow 
rate, IPSS: International Prostate Symptom Score, 
a: significant
difference (p＜0.05) between the two groups
inhibits both types I and II. Of the studies that have been 
conducted to date, not many have made comparisons be-
tween the two drugs. Some studies have reported that there 
are no great discrepancies in the effects and side effects. 
Other studies have reported that the concentration of se-
rum dihydrotestosterone (DHT) was suppressed more 
powerfully by dutasteride than by finasteride after a 
6-month administration [5].
　Regarding the effects of each treatment agent, many 
studies have been conducted to evaluate a single treatment 
or a concomitant treatment with α-blocker during a certain 
length of time or a long-term period. However, no clinical 
studies have been conducted to compare these two drugs, 
whose effects are based on totally different modes of action. 
We therefore compared the clinical effects of finasteride 
and dutasteride in BPH patients after 1 year of treatment.  
MATERIALS AND METHODS
We retrospectively investigated patients who were more 
than 50 years old with lower urinary tract symptoms be-
tween January 2005 and December 2008. The patients had 
been taking medication for treatment of BPH (alfuzosin 10 
mg, finasteride 5 mg, dutasteride 0.5 mg) for 1 year. The 
patients were classified into the alfuzosin＋finasteride 
combination therapy group and the alfuzosin＋dutasteride 
combination therapy group. At the early stage outpatient 
visit, all patients underwent transrectal ultrasonography 
and measurement of urine flow rate, residual urine vol-
ume, prostate-specific antigen (PSA), and International 
Prostate Symptom Score (IPSS). BPH was defined as cases 
in which the prostate volume exceeded 20 cc, the maximal 
flow rate was lower than 15 ml/s, and IPSS was higher than 
8 points in patients with lower urinary tract symptoms. A 
past history was also evaluated. Then, patients with any 
diseases affecting their voiding functions were excluded, 
such as vertebral diseases, cerebrovascular diseases, or di-
abetic peripheral diseases. Patients who had pyuria or in-
fections detected in urine chemistry and microbial tests 
were also excluded. Only patients who could be reevaluated 
after a 1-year period were enrolled.
　A total of 219 patients were enrolled in this study. To as-
sess the treatment effect between the groups, at the initial 
outpatient visit and after a 1-year period, a comparative 
analysis was performed for prostate volume, PSA, max-
imal flow rate, residual urine volume, and IPSS. The pro-
portion of each parameter was also examined. PSA was 
measured by electrochemiluminescence (ECLA, Modula, 
Roche Inc., Indianapolis, IN, USA). Statistical analysis 
was performed by using the SPSS ver. 10.0 (SPSS Inc., 
Chicago, IL, USA), for which an independent t-test was 
used. Statistical significance was set at p＜0.05. 
RESULTS
In the total group of 219 patients, the patients’ mean age 
was 69 years (range, 45-85 years), their mean prostate volume 
was 35.5±17.6 g, and their mean PSA level was 2.08±2.38 
ng/ml. A comparison of the treatment effect between the 
alfuzosin＋finasteride group and the alfuzosin＋dutas-
teride group showed no significant differences in the abso-Korean J Urol 2010;51:704-708
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lute changes in each parameter between the two groups 
(Table 1). However, the degree of PSA reduction was rela-
tively higher in the dutasteride combination therapy group 
(p= 0.020). The volume of the prostate gland was reduced, 
but this was not statistically significant (p=0.052) (Table 2). 
DISCUSSION
BPH is the most common cause of lower urinary tract symp-
toms in male patients, and it is a chronic, progressive di-
sease. At present, long-term drug treatment is the first- 
line treatment of choice, commonly with α-blockers. In ad-
dition, 5ARIs are both concomitantly administered or used 
as the sole treatment. 5ARI suppresses type I reductase, 
which is mainly present in the skin and liver, and type II 
reductase, which is specific to organs such as the prostate 
and male reproductive organ. By blocking the enzymatic 
conversion to DHT, it reduces the concentration of DHT 
within the prostate and thereby induces the degeneration 
of the prostatic gland. Finasteride, which is mainly specific 
to type II, reduces serum DHT by 70% and prostate DHT 
by 80-90% within 2 weeks after administration. Following 
a 12-month administration with a dose of 5 mg, the volume 
of the prostate has been reported to be reduced by approx-
imately 20% [6]. Dutasteride, which is specific to both types 
I and II, has also been reported to be effective in reducing 
prostate volume by approximately 23% after a 1-year admi-
nistration. Moreover, dutasteride has been reported to be 
effective in improving lower urinary tract symptoms such 
as IPSS or the maximal flow rate in male patients [7]. Some 
studies have suggested that dutasteride was more effective 
in suppressing DHT within the prostate as compared with 
finasteride (94-97% vs. 68-85%) [8-10]. Debruyne et al per-
formed an open marker test during a 2-year period after a 
2-year double-blind study [7]. According to those authors, 
following a comparison of IPSS between a 4-year dutas-
teride treatment group and a 2-year placebo treatment 
group, IPSS was significantly higher in the former group 
[7]. According to studies on prostate volume, in the finas-
teride group, there was an 18% decrease during a 4-year 
period. In the dutasteride group, however, there was a 
23.6% decrease during a 1-year period and a 27.3% de-
crease during a 4-year period [7,11]. In addition, there have 
also been studies that compared other aspects of finas-
teride and dutasteride treatment. For example, Fenter et 
al reported that dutasteride was effective in reducing medi-
cal expense by approximately 20% as compared with finas-
teride [12,13]. According to Roehrborn et al and O’Leary et 
al, dutasteride showed a higher degree of effect in improv-
ing symptoms [14,15]. Issa et al reported that the pro-
portion of acute urinary retention and that of surgical man-
agement were 5.3% vs. 8.3% and 1.4% vs. 3.4% after a 
5-month drug treatment with dutasteride vs. finasteride, 
respectively [16]. These results indicate that both parame-
ters were relatively lower in the dutasteride group than in 
the finasteride group. In our study, prostate volume and 
IPSS were relatively lower in the alfuzosin＋dutasteride 
group, but there were no statistically significant differ-
ences between the two groups (Table 1).
　Since PSA was disclosed to have a specificity for the pros-
tate in 1979, it has been used as a useful marker for the de-
tection of prostate cancer. However, PSA has also been 
shown to have a tendency to increase in other cases, such 
as prostatitis or BPH. Therefore, particularly in patients 
whose PSA level is 4-10 ng/ml, measurement of the PSA level 
does not have sufficient sensitivity and specificity to be a 
screening test for prostate diseases. Besides, the PSA level 
has also been reported to be affected by drugs that are com-
monly used to treat prostate diseases in the field of urology. 
Milam et al reported a lack of significant change in PSA in 
a study on α-blockers, especially terazosin [17]. In addition, 
Brown et al reported that the PSA level was decreased fol-
lowing a 2-month drug treatment [18]. As described here, 
there were no definite effects on the PSA level. Bozeman 
et al and Potts reported that the PSA level was decreased 
after treatment with quinolone antibiotics. Meanwhile, 
these authors maintained that unnecessary prostate biop-
sy should be reduced [19,20]. Fowke et al also reported that 
nonsteroidal antiinflammatory agents have been reported 
to significantly reduce the PSA level after treatment [21]. 
　Many studies have reported that 5ARI is effective in low-
ering the PSA level. In association with this, Guess et al 
reported that the PSA level was decreased by 50% after a 
1-year administration of finasteride 5 mg. After a 12-month 
period, however, there were no further effects in reducing 
the PSA level. Therefore, these authors maintained that 
the dose of finasteride should be determined to be twice the 
PSA level after a 1-year period [22]. In addition, Espana et 
al also advocated the “multiply by 2” principle, in which the 
dose should be multiplied by two based on the PSA level 
[23]. In Korea, Hong and Hong also reported that the PSA 
level was decreased by approximately 45% following a 
6-month administration of finasteride and by approx-
imately 50% following a 12-month administration [24]. 
Brawer et al reported that the PSA level was decreased by 
approximately 30-60% after a 54-week concomitant treat-
ment with α-blockers and 5ARI [25]. The Proscar Long- 
term Efficacy and Safety Study (PLESS) is a 4-year study 
of finasteride therapy with the application of the “multiply 
by 2” principle. It tried to analyze the diagnostic rate for 
prostate cancer based on a PSA level of 4 mg/ml. According 
to this study, there was a similar profile of sensitivity (66% 
vs. 70%) and specificity (82% vs. 74%) as compared with the 
placebo-controlled group when the actual PSA level was 
applied [26]. Regarding dutasteride, Andriole et al re-
ported that the PSA level was increased by 8.3% in year 2 
in the placebo-controlled group [27]. However, the PSA lev-
el was decreased by 59.5% in year 2 and by 66.1% in year 
4 in the dutasteride group. Based on these findings, the ap-
plication of the “double PSA (multiply by 2)” principle to 
treatment with finasteride should be effective, as shown for 
treatment with dutasteride, considering the sensitivity 
and specificity for the diagnosis of prostate cancer [27]. 
　In our study, when we compared the proportion of PSA Korean J Urol 2010;51:704-708
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alterations between the finasteride group and the dutas-
teride group, the degree of PSA reduction was significantly 
higher in the dutasteride group (0.85 vs. 0.67, p＜0.05) 
(Table 2). As for the reasons for these findings, no definite 
study results have been provided except that dutasteride 
has a dual effect, as compared with finasteride, and is more 
effective in suppressing DHT. However, according to 
Andriole et al, it has been theoretically hypothesized that 
dutasteride has an effectiveness in suppressing and necrot-
izing the proliferation of prostate cancer [28]. Also, in our 
series, in cases in which potential patients with prostate 
cancer were included, it can be presumed that this might 
cause a difference between tumor necrosis and the PSA lev-
el [28]. In the above studies, both finasteride and dutas-
teride were mentioned to be in need of application of the 
“multiply by 2” principle. According to our studies, however, 
it was questionable to consistently apply the “multiply by 
2” principle in making a diagnosis of prostate cancer in all 
patients who were treated with dutasteride. At present, on-
going efforts are being made to examine the effects of long- 
term administration of 5ARI in preventing prostate cancer. 
It would therefore be notable to determine whether there 
is an optimal method for monitoring the PSA level in cases 
in which 5ARI is administered long-term. In our study, we 
found that the PSA level can vary depending on the use of 
two different types of drugs. According to this, it is pre-
sumed that a precise measure rather than the simple appli-
cation of the “multiply by 2” principle would be mandatory.
　There are several limitations to our study. First, the 
number of cases enrolled in each group was small. Second, 
we could not perform a head to head study for each pure 
5ARI because of the limitations of a retrospective study. 
Therefore, to establish more precise criteria for prostate bi-
opsy in patients treated with 5ARI, an adequate number 
of cases and a well-designed prospective study are required. 
CONCLUSIONS
The degree of PSA reduction was significantly higher in the 
dutasteride group than in the finasteride group. It is there-
fore assumed that criteria for a screening test for prostate 
biopsy could be established on the basis of the degree of PSA 
reduction in patients whose PSA level was elevated. The 
difference between the two drugs should be clarified, and 
prostate biopsy should be performed accordingly with a 
consideration of the changes in the PSA level depending on 
the characteristics of the two different drugs. This would 
be helpful in the development of a screening test for pros-
tate cancer by reducing the number of unnecessary tests 
and raising the sensitivity and specificity.
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